

August 20, 2020

(1) BSE Ltd  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

(2) National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

### **Sub- Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("*Listing Regulations*"), we hereby notify that the Company's subsidiaries have signed following agreements:

1. "Business Transfer Agreement" between Quality Chemicals Limited, Uganda, ("*QCL*") and Cipla Quality Chemical Industries Limited, Uganda, ("*CQCIL*"), step-down subsidiaries of the Company, to sell Human Healthcare business of QCL to CQCIL, at a consideration of USD 1,271,747.
2. "Share Sale and Purchase Agreement" between Company's wholly owned subsidiary Cipla (EU) Limited, United Kingdom, QCL, Mr. Emmanuel Katangole, Mr. Fredrick Mutebi Kitaka and Mr. George Baguma to sell entire stake aggregating to 51% of the total paid-up equity share capital in QCL, held by Cipla (EU) Limited to Mr. Emmanuel Katangole, Mr. Fredrick Mutebi Kitaka and Mr. George Baguma for a total consideration of USD 344,239. Subsequent to the sale, QCL will cease to be a subsidiary of the Company.

A detailed disclosure as required under the Listing Regulations is enclosed as Annexure- I.

Thank you,

**For Cipla Limited**

---

**Rajendra Chopra**  
**Company Secretary**

Enclosed:

1. Details as per the Listing Regulations:

**Cipla Ltd.**

**Regd. Office** -Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

**P** +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-Mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

**Annexure - I**

**Sale of equity stake in Quality Chemicals Limited**

Sr. No.	Particulars	Details
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such subsidiary of the Company during the last financial year	<p>As on March 31, 2020</p> <ul style="list-style-type: none"> <li>• Total income is UGX 16,168,445,733 = 0.18% of Cipla Limited's consolidated turnover</li> <li>• Total Net worth is UGX 4,12,80,29,770 = 0.05% of Cipla Limited's consolidated Net worth</li> </ul>
b)	Date on which the agreement for sale has been entered into	August 20, 2020
c)	The expected date of completion of sale/disposal	August 30, 2020
d)	Consideration received from such sale/disposal;	<p>USD 344,239</p> <p>(USD 114 746 each from Mr. Emmanuel Katongole, Mr. Fredrick Mutebi Kitaka and Mr. George Baguma)</p>
e)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group /group companies. If yes, details thereof	<p>Mr. Emmanuel Katongole Mr. Katongole is a founding Director and shareholder of QCL. When QCL partnered with Cipla to form CQCIL, Mr Katongole was appointed as the Executive Chairman of the CQCIL board.</p> <p>Mr. Frederick Mutebi Kitaka Mr. Kitaka is a founding Director and shareholder of QCL. He served as Head of Finance at QCL from 1997 – 2005 and Chief Finance Officer at CQCIL from 2005-2014.</p> <p>Mr. George Baguma Mr. Baguma is a founding Director and shareholder of QCL and he served as the founding Chief Commercial Officer at CQCIL from 2000 to 2005.</p> <p>The Buyers do not belong to the promoter/promoter group/group companies.</p>
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No
g)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the Company with respect to such slump sale	Not Applicable